Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Joins Nasdaq-100

SAN FRANCISCO, Dec. 17 - Invitrogen will join 12 other companies that will be added to the Nasdaq-100 Index next Monday.


The Nasdaq-100, the 100 largest non-financial stocks on the Nasdaq Stock Market, is re-ranked every December. The rankings are based on a company's market capitalization, computed using closing prices as of October 31 and the publicly reported total shares outstanding as of November 30.


At the time of ranking, Invitrogen's market capitalization was $3.2 billion, according to Nasdaq.


"Our appointment to the Index is a testament to Invitrogen's rapid growth and consistent performance throughout its history and since becoming a public company in 1999," Lyle Turner, CEO of Invitrogen, said in a statement.


Eight of this year's 13 additions to the Nasdaq-100 are life science-oriented companies. Corporations listed in the Index are included in the Nasdaq-100 Index Tracking Stock, the world's most actively traded exchange-traded fund, according to Nasdaq.


In early December, Invitrogen, based in San Diego, Calif., said it plans to post $628 million in revenues for the year, which will surpass by 155 percent 2000 sales.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.